BFRG vs. RLMD, ORMP, CMRX, IFRX, HILS, ASMB, SLS, ONCY, MIST, and PYRGF
Should you be buying Bullfrog AI stock or one of its competitors? The main competitors of Bullfrog AI include Relmada Therapeutics (RLMD), Oramed Pharmaceuticals (ORMP), Chimerix (CMRX), InflaRx (IFRX), Hillstream BioPharma (HILS), Assembly Biosciences (ASMB), SELLAS Life Sciences Group (SLS), Oncolytics Biotech (ONCY), Milestone Pharmaceuticals (MIST), and PyroGenesis Canada (PYRGF). These companies are all part of the "pharmaceutical preparations" industry.
Relmada Therapeutics (NASDAQ:RLMD) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, community ranking, dividends and media sentiment.
Bullfrog AI's return on equity of -102.09% beat Relmada Therapeutics' return on equity.
Relmada Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.
In the previous week, Bullfrog AI had 1 more articles in the media than Relmada Therapeutics. MarketBeat recorded 4 mentions for Bullfrog AI and 3 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.19 beat Bullfrog AI's score of 0.58 indicating that Bullfrog AI is being referred to more favorably in the news media.
Bullfrog AI has higher revenue and earnings than Relmada Therapeutics. Bullfrog AI is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.
Relmada Therapeutics received 16 more outperform votes than Bullfrog AI when rated by MarketBeat users.
45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are held by institutional investors. 18.0% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Relmada Therapeutics presently has a consensus price target of $25.00, suggesting a potential upside of 733.33%. Given Bullfrog AI's higher possible upside, equities analysts plainly believe Relmada Therapeutics is more favorable than Bullfrog AI.
Summary
Relmada Therapeutics beats Bullfrog AI on 7 of the 13 factors compared between the two stocks.
Get Bullfrog AI News Delivered to You Automatically
Sign up to receive the latest news and ratings for BFRG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BFRG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bullfrog AI Competitors List
Related Companies and Tools
